ЛИПОПРОТЕИН(А) И АТЕРОСКЛЕРОТИЧЕСКИЕ СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ: РОЛЬ И ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ РЕЗУЛЬТАТОВ ИССЛЕДОВАНИЙ
Аннотация
Липиды и частицы липопротеинов обуславливают развитие атеросклероза и определяют риск сердечно-сосудистых заболеваний. Помимо общего холестерина, липопротеинов низкой и высокой плотности (ЛПНП, ЛПВП), также другие липидные медиаторы способствуют сердечно-сосудистому риску. Липопротеин(а) (Лп(a)) – один из них. В настоящее время рекомендации и консенсусные заявления рекомендуют измерение Лп(а) у всех взрослых хотя бы один раз в жизни. Лп(а) состоит из ЛПНП-подобной частицы, в которой апобелок(а) посредством одной дисульфидной связи ковалентно связан с апобелком В100. Уровень Лп(а) – генетически обусловленная особенность. Цель. Провести анализ литературы по клиническому значению липопротеин(а) в развитии сердечно-сосудистых заболеваний. Материал и методы. Проанализировано 46 литературных источников. Выводы. Учитывая четкие литературные данные, указывающие на связь Лп(а) с сердечно-сосудистыми заболеваниями в качестве независимых факторов атерогенеза и тромбогенеза, несомненный интерес вызывает изучение роли Лп(а) в развитии сердечно-сосудистых событий.
Литература
Visseren FLJ, Mach F, Smulderst YM, Carballot D, Koskinas KC, Bäck M, Benetos Abiffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, DI Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, et at. 2021 ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Russian Journal of Cardiology. 2022;27(7):191-288. https://doi.org/10.15829/1560-4071-2022-5155. https://www.elibrary.ru/vqdnik. (Russian).
Yaroustovsky MB, Abramyan MV, Rogalskaya EA, Komardina EV, Nazarova EI, Grigoryan DA, Podschekoldina OO. Рossibilities of correction of elevated lipoprotein (a) levels. Creative Cardiology. 2019;13(2):129-146. https://doi.org/10.24022/1997-3187-2019-13-2-129-146. https://www.elibrary.ru/nusbuh. (Russian).
Tsygankova OV, Bondareva KI, Latyntseva LD, Starichkova AA. Clinical and pathophysiological role of lipoprotein (a) in the development of diseases associated with atherosclerosis. RMJ. 2020;28(12):4-8. edn:JHRWII. (Russian).
Tikhonov AV. Lipoprotein(a) and atherosclerosis. Ateroscleroz. 2007;3(1):3-23. edn: NXXTHJ. (Russian).
Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, Liu L. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. J. Am. Coll. Cardiol. 2018;71(2):177-192. https://doi.org/10.1016/j.jacc.2017.11.014.
Velkov VV. Lipoprotein (a): new perspectives for laboratory diagnosis. Kliniko-laboratornyj konsilium. 2012;4(44):37-48. edn: NBLZTP. (Russian).
Kamstrup PR. Lipoprotein(a) and Cardiovascular Disease. Clin. Chem. 2021;67(1):154-166. https://doi.org/10.1093/clinchem/hvaa247.
Hopewell JC, Haynes R, Baigent K. The role of lipoprotein(a) in chronic kidney disease. J. Lipid Res. 2018;59(4):577-585. https://doi.org/10.1194/jlr.R083626.
Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology. J. Lipid Res. 2016;57(11):1953-1975. https://doi.org/10.1194/jlr.R071233.
Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J. Lipid Res. 2016;57(8):1339-1359. https://doi.org/10.1194/jlr.R067314.
Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53-62. https://doi.org/10.1016/j.atherosclerosis.2022.04.006.
Kanbay M, Delibasi T, Kaya A, Aydogan T, Koca C, Akcay A, Duranay M, Yigitoglu R. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins. Ren Fail. 2006;28(7):567-571. https://doi.org/10.1080/08860220600839761.
Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, Bjornsson E, Norddahl GL, Jonasdottir A, Jonasdottir A, Eggertsson HP, Gretarsdottir S, Thorleifsson G, Indridason OS, Palsson R, Jonasson F, Jonsdottir I, Eyjolfsson GI, Sigurdardottir O, Olafsson I, Danielsen R, Matthiasson SE, Kristmundsdottir S, Halldorsson BV, Hreidarsson AB, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982-2994. https://doi.org/10.1016/j.jacc.2019.10.019.
Kaiser Y, Daghem M, Tzolos E, Meah MN, Doris MK, Moss AJ, Kwiecinski J, Kroon J, Nurmohamed NS, van der Harst P, Adamson PD, Williams MC, Dey D, Newby DE, Stroes ESG, Zheng KH, Dweck MR. Association of lipoprotein(a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79(3):223-233. https://doi.org/10.1016/j.jacc.2021.10.044.
Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, Krone W, Laudes M. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One. 2010;5(12):e14328. https://doi.org/10.1371/journal.pone.0014328.
Maranhão RC, Carvalho PO, Strunz CC, Pileggi F. Lipoprotein (a): Structure, pathophysiology and clinical implications. Arq. Bras. Cardiol. 2014;103(1):76-84. https://doi.org/10.5935/abc.20140101.
Jawi MM, Frohlich J, Chan SY. Lipoprotein (a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein (a) Molecule. J Lipids. 2020;2020:3491764. https://doi.org/10.1155/2020/3491764.
Derby CA, Crawford SL, Pasternak RC, Sowers M, Sternfeld B, Matthews KA. Lipid changes during the menopause transition in relation to age and weight: The Study of Women’s Health Across the Nation. Am. J. Epidemiol. 2009;169(11):1352-61. https://doi.org/10.1093/aje/kwp043.
Iannuzzo G, Tripaldella M, Mallardo V, Morgillo M, Vitelli N, Iannuzzi A, Aliberti E, Giallauria F, Tramontano A, Carluccio R, Calcaterra I, Di Minno MND, Gentile M. Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. Biomedicines. 2021;9(7):838. https://doi.org/10.3390/biomedicines9070838.
Gabel BR, Koschinsky MI. Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a). Biochemistry. 1995;34(48):15777-15784. https://doi.org/10.1021/bi00048a023.
Coassin S, Kronenberg F. Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis. 2022;349:17-35. https://doi.org/10.1016/j.atherosclerosis.2022.04.003.
Bostom AG, Gagnon DR, Cupples LA, Wilson PW, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994;90(4):1688-1695. https://doi.org/10.1161/01.cir.90.4.1688.
Shai I, Rimm EB, Hankinson SE, Cannuscio C, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J. Lipoprotein (a) and coronary heart disease among women: beyond a cholesterol carrier? Eur Heart J. 2005;26(16):1633-1639. https://doi.org/10.1093/eurheartj/ehi222.
Cantin B, Després JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, Dagenais GR. Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men: the Quebec Cardiovascular Study. Am J Cardiol. 2002;89(6):662-666. https://doi.org/10.1016/s0002-9149(01)02336-0.
Guerra R, Yu Z, Marcovina S, Peshock R, Cohen JC, Hobbs HH. Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation. 2005;111(12):1471-1479. https://doi.org/10.1161/01.CIR.0000159263.50305.BD.
Kamstrup PR, Nordestgaard BG. Elevated lipoprotein(a) levels, LPA risk genotypes, elevated lipoprotein(a) levels, LPA risk genotypes, and increased risk of heart failure in the general population. JACC Heart Fail. 2016;4(1):78-87. https://doi.org/10.1016/j.jchf.2015.08.006.
Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54-66. https://doi.org/10.1016/j.jacc.2019.03.524.
Cairns BJ, Coffey S, Travis RC, Prendergast B, Green J, Engert JC, Lathrop M, Thanassoulis G, Clarke R. A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data. Circulation. 2017;135(12):1181-1183. https://doi.org/10.1161/CIRCULATIONAHA.116.026103.
Kaiser Y, Singh SS, Zheng KH, Verbeek R, Kavousi M, Pinto SJ, Vernooij MW, Sijbrands EJG, Boekholdt SM, de Rijke YB, Stroes ESG, Bos D. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart. 2021;107(17):1422-1428. https://doi.org/10.1136/heartjnl-2021-319044.
Kronenberg F. Genetic determination of lipoprotein(a) and its association with cardiovascular disease. Convenient does not always mean better. J Intern Med. 2014;276(3):243-247. https://doi.org/10.1111/joim.12207.
Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. Ascientific statement from the national lipid association. J Clin Lipidol. 2019;13(3):374-392. https://doi.org/10.1016/j.jacl.2019.04.010.
Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol 2022;42(1):e48-e60. https://doi.org/10.1161/ATV.0000000000000147.
Coassin S, Erhart G, Weissensteiner H, Eca Guimarães de Araújo M, Lamina C, Schönherr S, Forer L, Haun M, Losso JL, Köttgen A, Schmidt K, Utermann G, Peters A, Gieger C, Strauch K, Finkenstedt A, Bale R, Zoller H, Paulweber B, Eckardt KU, Hüttenhofer A, Huber LA, Kronenberg F. A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. EurоHeart J. 2017;38(23):1823-1831. https://doi.org/10.1093/eurheartj/ehx174.
Schachtl-Riess JF, Kheirkhah A, Grüneis R, Di Maio S, Schoenherr S, Streiter G, Losso JL, Paulweber B, Eckardt KU, Köttgen A, Lamina C, Kronenberg F, Coassin S. Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease. J Am Coll Cardiol. 2021;78(5):437-449. https://doi.org/10.1016/j.jacc.2021.05.037.
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455.
Pearson GJ, Thanassoulis G, Anderson TJ, Barry AR, Couture P, Dayan N, Francis GA, Genest J, Grégoire J, Grover SA, Gupta M, Hegele RA, Lau D, Leiter LA, Leung AA, Lonn E, Mancini GBJ, Manjoo P, McPherson R, Ngui D, Piché ME, Poirier P, Sievenpiper J, Stone J, Ward R, et al. 2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol. 2021;37(8):1129-1150. https://doi.org/10.1016/j.cjca.2021.03.016.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet Lond Engl. 2018;392(10155):1311-20. https://doi.org/10.1016/S0140-6736(18)31652-0.
Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2020;41(24):2275-84. https://doi.org/10.1093/eurheartj/ehz310.
Safarova MS, Ezhov MV. The evolution of views on lipoprotein(a): from biomarker to the therapeutic target. Cardiology. 2015;55(4):71-82. https://doi.org/10.18565/cardio.2015.4.71-82. https://www.elibrary.ru/txkqlf. (Russian).
Тrinder M, Paruchuri K, Haidermota S, Bernardo R, Zekavat SM, Gilliland T, Januzzi JJr, Natarajan P. Repeat measures of lipoprotein(a) molar concentration and cardiovascular risk. J Am Coll Cardiol. 2022;79(7):617-628. https://doi.org/10.1016/j.jacc.2021.11.055.
Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokgözoğlu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-46. https://doi.org/10.1093/eurheartj/ehac361.
Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255-67. https://doi.org/10.1056/NEJMoa1107579.
Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, lowdensity lipoprotein cholesterol and lipoprotein (a). Pharmaceuticals. 2023;16(4):577. https://doi.org/10.3390/ph16040577.
Yeang C, Karwatowska-Prokopczuk E, Su F, Dinh B, Xia S, Witztum JL, Tsimikas S. Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol. J Am Coll Cardiol. 2022;79(11):1035-46. https://doi.org/10.1016/j.jacc.2021.12.032.
O’Donoghue ML, Rosenson RS, Gencer B, Antonio J. Association of baseline lipoprotein(a) and percentage of lipoprotein(a) lowering with olpasiran. J Am Coll Cardiol. 2023;81(8):1130. https://doi.org/10.1016/S0735-1097(23)01574-7/
Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330(11):1042-53. https://doi.org/10.1001/jama.2023.16503.
